Influence of delivery on plasminogen activator inhibitor activity by Koelbl, Heinz et al.
Koelbl et al, Changes of the fibrinolytic system before and after delivery 107
J. Perinat. Med.
17 (1989) 107
Influence of delivery on plasminogen activator inhibitor activity
Heinz Koelbl1, Johannes Kirchheimer2, and Gerhart Tatra1
*2nd Department of Obstetrics and Gynecology and laboratory for Clinical-
Experimental Physiology at the Department of Medical Physiology, University of
Vienna, Austria
1 Introduction
Plasminogen activators are serine proteases which
initiate the fibrinolytic system by conversion of
the proenzyme plasminogen to the active fibrin
degrading enzyme plasmin. Two different types of
plasminogen activators have been characterized:
A urokinase-type plasminogen activator (u-PA) is
produced and secreted by several cells and found
in different body fluids. Tissue-type plasminogen
activator (t-PA) is mainly responsible for activat-
ing the fibrinolytic defence system against throm-
bosis. Plasminogen activator inhibitors (PAI)
found in endothelial cells and the placenta inhibit
the effects of both plasminogen activators [18].
Changes of plasma concentrations of plasminogen
activators and their inhibitors are found under
various physiological and pathophysiological con-
ditions. Hypoxia, venous occlusion, vein throm-
bosis, prostaglandines and histamine cause an al-
teration of plasma t-PA antigen levels [10, 12, 21,
24]. An increase of u-PA was found in patients
with malignant disease and inflammations [13,24].
PAI changes were observed in patients with venous
thrombosis, malignant disease, myocardial infarc-
tion and are released by endotoxins and stress [6,
10, 21, 25].
Uncomplicated pregnancies are accompanied by
hypercoagulability and an increased risk of throm-
boembolic disease. Thrombosis is rare in the first
trimester and most events are noted in the last
trimester.
In this study we measured plasma levels of plas-
minogen activators and their inhibitors in women
with uncomplicated pregnancy near term and after
delivery.
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2 Patients and methods
Fourty-four healthy women (age, mean + SD:
24.3 ± 4.3 yrs) with uncomplicated full term preg-
nancies were studied. The timing of the blood
samples was as follows: (1) before the onset of
labour without rupture of the foetal membranes
and without uterine contractions, (2) from the first
to the fifth day after delivery. Blood samples (10
ml) were collected with ethylenediaminetetraacetic
acid (EDTA, 5 mM) as anticoagulant, by veni-
puncture from the antecubital vein with minimal
venous occlusion. Platelet-poor plasma was ob-
tained immediately by centrifugation at 2000 g for
20 min at 4 °C. Aliquots for the respective deter-
mination were stored at — 70 °C until used.
2.1 Determination of u-PA antigen
Urokinase antigen levels were determined in
plasma using a competitive radioimmunoassay
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for high molecular weight urokinase [9]. All de-
terminations were done in triplicate. The lower
detection limit was 50 pg urokinase antigen/ml,
the intraassay variation was approximately 4%
and the interassay variation approximately 6%
[8].
2.2 Determination of t-PA antigen
T-PA antigen was determined with a sandwich
ELISA employing two monoclonal antibodies
against human t-PA [5, 20, 26]. All determinations
were done in duplicate. The lower detection limit
of the assay was 0.5 ng/ml, the intraassay variation
5% and the interassay variation 10% [26]. The
value obtained correlated with a sandwich ELISA
using a polyclonal and a monoclonal antibody
also developed in our laboratory [15].
2.3 Determination of PAI activity
Determination of PAI activity was performed us-
ing a functional assay measuring the inhibition
rate of purified single chain t-PA by plasma sam-
ples as published previously [14, 23]. The PAI
assay used in this study is a functional assay in-
capable of distinguishing immunologically distinct
PAIs derived from different sources i. e. placenta,
vascular endothelium or platelets [27]. The intraas-
say coefficient of variation was 8% and the inter-
assay coefficient of variation was 11% [14].
2.4 Statistical analysis
Mean values and the SD of the plasma levels of
the different parameters were calculated from all
values obtained before and after delivery. Signifi-
cant differences in the plasma levels of the different
observations and respective age-matched control
patients [11] were calculated using Wilcoxon test
for unpaired observations. Significance was as-
signed for ρ < 0.05. Linear correlations were cal-
culated between the values of the different com-
ponents of the fibrinolytic system for each time
separately and between these parameters.
3 Results
The plasma levels of u-PA antigen, t-PA antigen
and PAI activity of 44 healthy women before and
after delivery were compared with the values ob-
tained from the age-matched healthy control
group (table).
Before the onset of labour no significant difference
was found for u-PA and t-PA antigen in compar-
ison to an age-matched control group. In the puer-
perium the mean plasma antigen levels of both
plasminogen activators remained unchanged. In
addition, no influence of birth weight and placen-
tal weight was found on t-PA and u-PA plasma
levels (p > 0.05).
Compared to an age-matched, non-pregnant con-
trol group a significant increase of PAI activity
was found in women before delivery (p < 0.005).
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However, one day after delivery the PAI activity
levels were significantly lower than during the last
period of pregnancy (p < 0.005). Compared to the
control group no significant difference was ob-
served for PAI activity one day post partum and
levels remained unchanged until the fifth day after
delivery.
4 Discussion
Our results show, that t-PA antigen levels at the
end of pregnancy are the same as in non pregnant
women. We think that the high level of PAI is
responsible for the depressed fibrinolytic activity
at the end of pregnancy [1]. These findings are in
contrast to those of Kruithof et al., who observed
an increase of u-PA and t-PA of 50% and 200%,
respectively [16].
We found a significant increase of PAI activity in
pregnant women near term. This observation is in
accordance to reduced fibrinolytic activity during
pregnancy as described by Astedt [4] and Stirling
[22]. In addition, Gore [8] found significantly in-
creased levels of a fast-acting tissue plasminogen
activator inhibitor throughout pregnancy.
Furthermore, we observed a significant decrease
of PAI activity at the first day after delivery. These
observations are in accordance to those of Lecan-
der [17], who isolated a specific plasminogen ac-
tivator inhibitor with a molecular weight of 70.000
daltons, increasing successively during pregnancy
and falling sharply after delivery.
Our data indicate that this decrease in PAI might
be caused by removal of the placenta. Recently
the localisation of a placental type plasminogen
activator inhibitor in the trophoblastic epithelium
was demonstrated by Astedt [2] using immuno-
histochemical methods. Whereas the localization
in the trophoblast does not clearly indicate that
these cells are the source of placental PAI a purely
storage function is not excluded by the authors.
The trophoblastic epithelial cells are in direct con-
tact with the maternal blood and a passage of the
protein into the maternal circulation is discussable
[3].
The placenta has been estimated to be the most
likely source of a pregnancy plasma plasminogen
activator inhibitor as described by Lecander [17].
The rapid disappearance of this pregnancy-specific
PAI is suggested by a short half-life. Compared
to non pregnant women similar PAI activity was
measured in the blood samples collected in the
puerperium. Probably release of maternal produc-
tion of normal non-pregnancy PAI is responsible
for PAI activity present after delivery as reported
by Mackinnon [19].
In conclusion, an increased PAI activity seems to
be responsible for depressed fibrinolytic activity
during pregnancy with a subsequent decline to
normal range at 24 hours after delivery, obviously
caused by the removal of the placenta.
Summary
Plasminogen activators initiate the fibrinolytic system
by conversion of the proenzyme plasminogen to the
active fibrin degrading enzyme plasmin. Plasminogen
activator inhibitors inhibit the effects of both plasmin-
ogen activators. Uncomplicated pregnancies are accom-
panied by hypercoagulability and an increased risk of
thromboembolic disease. Thrombosis is rare in the first
trimester and most events are noted in the last trimester.
Therfore, we studied the fibrinolytic system at the end
of pregnancy and in the puerperium. Plasma concentra-
tions of urokinase plasminogen activator (u-PA/com-
petitive radioimmunoassay), tissue type plasminogen Ac-
tivator (t-PA/sandwich ELISA) and plasminogen acti-
vator inhibitor (PAI/functional assay) were determined
in 44 women (age: 24.3 ±4.3 years) with normal preg-
nancy near term. Plasma samples were collected before
the onset of labour and 1, 2, 3, 4 and 5 days after
delivery. Compared with an age-matched non pregnant
control group (8.3 + 3.94 U/ml) significantly increased
PAI activity (12.13 ± 4.79 U/ml - p < 0.005) was
measured before delivery with a subsequent significant
decrease (8.13 ± 1.97 U/ml) to normal values on day 1
after delivery; plasma u-PA and t-PA antigen levels re-
mained unchanged. Placental weight and birth weight
had no influence on plasma levels of both plasminogen
activators.
Keywords: Plasminogen activators, plasminogen activator inhibitor, pregnancy, puerperium.
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Der Einfluß der Geburt auf die Aktivität des Plasmino-
genaktivatorinhibitors
Das fibrinolytische System wird durch Plasminogenak-
tivatoren, die die Umwandlung des Proenzyms Plasmi-
nogen in das Enzym Plasmin bewirken, in Gang ge-
bracht. Plasminogenaktivator-Inhibitoren hemmen die
Wirkung beider Plasminogenaktivatoren. Unkompli-
zierte Schwangerschaften sind von einem Zustand der
Hyperkoagulabilität und einem erhöhten Thromboseri-
siko begleitet. Letzteres ist selten im ersten Trimenon
und die meisten thromboembolischen Komplikationen
werden im dritten Trimenon beobachtet. Dies war An-
laß, das fibrinolytische System am Ende der Schwanger-
schaft und im Wochenbett zu untersuchen. Plasmakon-
zentrationen von Urokinase-Typ Plasminogenaktivator
(u-PA/kompetitiver Radio-immunoassay), Gewebe-Typ
Plasminogenaktivator (t-PA/sandwich ELISA) und Plas-
minogenaktivator-Inhibitor (PAI/funktioneller Test)
wurden bei 44 Frauen (Alter: 24.3 ± 4.3 Jahre) mit
normaler und nahezu ausgetragener Schwangerschaft
bestimmt. Plasmaproben wurden vor der Geburt und
am 1., 2., 3., 4. und 5. Tag post partum gewonnen.
Gegenüber einer altersentsprechenden nicht schwange-
ren Kontrollgruppe (8.3 ± 3.94 U/ml) fanden wir einen
signifikanten Anstieg der PAI-Aktivität (12.13 ± 4.79
U/ml - p < 0.005) vor der Geburt. Bereits am 1. Tag
post partum kam es zu einem signifikanten Absinken
der PAI Werte (8.13 ± 1.97 U/ml) bis in den Normbe-
reich. Plasma u-PA und t-PA Antigenspiegel zeigten
gegenüber der Kontrollgruppe weder vor der Geburt
noch im Wochenbett Veränderungen. Ein Zusammen-
hang zwischen Plazentagewicht, Geburtsgewicht und
den Plasmakonzentrationen der Plasminogenaktivatoren
war nicht herzustellen.
Schlüsselwörter: Plasminogenaktivatoren, Plasminogenaktivator-Inhibitor, Schwangerschaft, Wochenbett.
Resume
Influence de la naissance sur l'activite de Pinhibiteur des
activateurs du plasminogene
Le Systeme fibrinolytique est active par les activateurs
du plasminogene qui transforment la proenzyme plas-
minogene en enzyme plasmine. Les inhibiteurs des ac-
tivateurs du plasminogene (PAI) inhibent les effets des
deux activateurs du plasminogene. Les grossesses nor-
males d'accompagnent d'une hypercoagulabilite et d'un
risque de complications thromboemboliques. Les throm-
boses sont rares au premier trimestre, et frequentes en
fin de grossesse. Pour cette raison, nous avons analyse
le Systeme fibrinolytique en fin de gestation et pendant
la phase puerperale. Les concentrations plasmatiques de
Pactivateur du plasminogene du type de Purokinase (u-
PA/radioimmunoassäy competitive), de Pactivateur du
plasminogene du type du tissue (t-PA/sandwich ELISA)
et du PAI (test functional) ont ete determinees ctiez 44
femmes (äge: 24,3 + 4,3 ans) avec une gestation nor-
male, pres de la delivrance. Des prelevements ont ete
effectues avant le commencement des contractions et au
ler, 2eme, 3eme, 4eme et Seme jours post partum. Nous
avons trouve une activite du PAI significativement elevee
(12,13 + 4,79 U/ml - p < 0,005) avant la delivrance
en comparaison d'un groupe controle, du meme äge et
non enceinte (8,3 + 3,94 U/ml). L'activite du PAI etait
redescendue aux valeurs normales au premier jour du
post partum (8,13 + 1,97 U/ml). Les concentrations
plasmatiques de Pu-PA et de t-PA ne changent pas avant
ou apres la delivrance. Les poids du placenta et du
nouveau-ne n'influencent pas les concentrations des deux
activateurs du plasminogene.
Mots-cles: Activateurs du plasminogene, grossesse, inhibiteur des activateurs fu plasminogene, phase puerperale.
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